RxDoctor Payments Data

Naveen Devabhaktuni, MD

Cardiovascular Disease · Evansville, INNPI 1679586705

Payments from drug & device makers

$3,378in general payments, 2019–2025

Across 210 payments — averaging $16.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$635
  • Johnson & Johnson$583
  • E.r. Squibb & Sons, L.L.C.$369
  • Merck$304
  • Boston Scientific$186
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$181
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,35999%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,378 in reported general payments places this provider in the 50th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$232,464
Medicare patients
1,993
Services billed
4,189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban174$190,221
FarxigaDapagliflozin Propanediol123$107,474
JardianceEmpagliflozin93$83,045
EntrestoSacubitril/Valsartan54$70,007
XareltoRivaroxaban64$67,512
Repatha SureclickEvolocumab40$45,977
Metoprolol Succinate507$5,995
Ranolazine ErRanolazine40$5,040
Isosorbide Mononitrate ErIsosorbide Mononitrate232$2,156
Diltiazem 24hr Er (Cd)Diltiazem Hcl70$1,850
Potassium Chloride68$1,375
Rosuvastatin Calcium151$1,351
Amlodipine Besylate233$1,327
Losartan Potassium189$1,212
Atorvastatin Calcium183$1,189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$112$190,221174 claims
AstraZenecaFarxiga$66$107,474123 claims
Boehringer IngelheimJardiance$147$83,04593 claims
NovartisEntresto$635$70,00754 claims
Johnson & JohnsonXarelto$583$67,51264 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →